Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea.
- Author:
Min Hee HONG
1
;
Hyo Song KIM
;
Chan KIM
;
Jung Ryun AHN
;
Hong Jae CHON
;
Sang Joon SHIN
;
Joong Bae AHN
;
Hyun Cheol CHUNG
;
Sun Young RHA
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. rha7655@yuhs.ac
- Publication Type:Original Article
- Keywords:
Renal cell carcinoma;
Sunitinib;
Korea;
Efficacy;
Toxicity
- MeSH:
Alanine Transaminase;
Anemia;
Appointments and Schedules;
Aspartic Acid;
Carcinoma, Renal Cell;
Creatinine;
Disease-Free Survival;
Fatigue;
Hand-Foot Syndrome;
Humans;
Indoles;
Korea;
Neutropenia;
Pyrroles;
Retrospective Studies;
Stomatitis;
Thrombocytopenia
- From:Cancer Research and Treatment
2009;41(2):67-72
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The retrospective study was performed to assess the efficacy and toxicity profiles of sunitinib in Korean patients with metastatic renal cell carcinoma (RCC). MATERIALS AND METHODS: Between January 2005 and December 2008, 76 Korean patients with recurrent/metastatic RCC who received sunitinib were retrospectively reviewed. The primary end point was progression-free survival and the secondary end points were overall survival and response rate. We also assessed the toxicities associated with sunitinib treatment. RESULTS: Of the 76 patients, 69 (90.1%) were diagnosed with clear cell RCC. The median progression-free survival and overall survival were 7.2 and 22.8 months, respectively in overall patients. Sixty-two patients (81.6%) received 50 mg 4 week and 2 week off schedule, and 14 patients (18.4%) received 37.5 mg daily on a daily continuous schedule. The objective response rate and disease control rate were 27.6% and 84.2%, respectively. A dose reduction or reduction in dose due to adverse events occurred in 76% of the patients, whereas 11% of the patients had discontinued treatment. Other common laboratory abnormalities were increased serum creatinine (75.6%), elevated alanine aminotransferase (71.0%), neutropenia (61.8%), anemia (69.7%), and increased aspartate aminotrasferase (53.3%). Grade 3/4 toxicities occurred as follows: thrombocytopenia (38.2%), fatigue (10.5%), stomatitis (10.5%), and hand-foot syndrome (9.2%). CONCLUSION: Our results indicate that sunitinib treatment is effective and tolerable for ecurrent/metastatic RCC patients in Korea. Further studies with prognostic or biochemical factors are needed to clarify the different toxicity profiles of this study.
